AAN 2026 | Combining lifestyle interventions and anti-amyloid therapies in Alzheimer’s disease

Majid Fotuhi, MD, PhD, Johns Hopkins University, Washington, D.C., discusses the complementary role of lifestyle interventions and anti amyloid monoclonal antibodies in early Alzheimer’s disease. He explains how lifestyle strategies may support brain health through improved blood flow, sleep, and inflammation control, while monoclonal antibodies specifically target amyloid pathology. Dr Fotuhi also shares his perspective on sequencing approaches, emphasizing lifestyle interventions as the foundation of long term brain health. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.